ASA 81 MG TABLET (DELAYED-RELEASE)

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

ACETYLSALICYLIC ACID

Предлага се от:

PHARMASCIENCE INC

АТС код:

B01AC06

INN (Международно Name):

ACETYLSALICYLIC ACID

дозиране:

81MG

Лекарствена форма:

TABLET (DELAYED-RELEASE)

Композиция:

ACETYLSALICYLIC ACID 81MG

Начин на приложение:

ORAL

Броя в опаковка:

120

Вид предписание :

OTC

Терапевтична област:

SALICYLATES

Каталог на резюме:

Active ingredient group (AIG) number: 0101169013; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2001-11-30

Данни за продукта

PRODUCT MONOGRAPH
ASA 81 MG
Acetylsalicylic
Acid Delayed-release Tablets USP
81 mg
ASA DAILY LOW DOSE
Acetylsalicylic
Acid Tablets USP
81 mg
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Quebec H4P 2T4
DATE OF REVISION:
March 14, 2022
www.pharmascience.com
SUBMISSION CONTROL NUMBER: 261509, 261543
Page 2 of 42
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................5
ADVERSE
REACTIONS..............................................................................................7
DRUG INTERACTIONS
..............................................................................................8
DOSAGE AND ADMINISTRATION
.........................................................................
10
OVERDOSAGE
.........................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
11
STORAGE AND STABILITY
....................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
................................................................... 13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 13
PART II : SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
.....................................................................
15
CLINICAL TRIALS
...........................................................................................